Oral mucositis is a common adverse reaction of standard stomatotoxic chemotherapy regimens for the treatment of cancer. It starts 5 -10 days after chemotherapy begins and lasts 7-14 days. The chemotherapy causes the mucosal lining of the mouth to shrink and break down, resulting in ulcers.
Mucositis can create additional difficulty for a patient while undergoing chemotherapy. It has the potential to reduce quality of life and increase difficulty with eating. Revive Research Institute is conducting a study on a medical device, Chemo Mouthpiece, that delivers cryotherapy to the oral mucosa. The goal of this clinical trial is to mitigate the reported symptoms associated with oral mucositis in patients receiving standard stomatotoxic chemotherapy.
Participation Criteria :
- Adults 18-80 years of age, male or female
- Planning to receive at least 2 cycles of infused somatotoxic chemotherapy regimens (such as: CMF, AC+T, ABVD, FOLFIRI, or any other 5-FU-based regimen)
- Comply with all the study procedures
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.